Quick Links
Past Events

Credit Designation

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this live activity for 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.0 Contact Hour.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Lilly.

For further information concerning Lilly grant funding, visit

Privacy Policy
Terms & Conditions
Executive Board
Faculty Portal
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 1-609-378-3701

Copyright © 2019
Physicians’ Education Resource ®, LLC.
All rights reserved.

Oncology Best Practice™: Decision Points in Advanced NSCLC: Assessing Treatment Options in the Second Line and Beyond

Oncology Best Practice™: Decision Points in Advanced NSCLC: Assessing Treatment Options in the Second Line and Beyond

In order to request this CME/CE activity for your center, please contact Samantha Zelasko at or call (609) 325-4668

Oncology Best Practice™:
Decision Points in Advanced NSCLC: Assessing Treatment Options Beyond Disease Progression


The management of patients with advanced non–small cell lung cancer (NSCLC) who have progressed following first-line therapy has increased in complexity due to the expanding subtypes of NSCLC and corresponding therapeutic options recently made available. As new biomarkers and patient characteristics continue to emerge that assist clinicians in predicting responsiveness to particular approaches, practitioners will need updates that allow them to optimize outcomes in lung cancer management. Education is therefore needed to address the evidence that informs therapeutic selection after disease progression, circumstances that should guide switching of therapies, and methods to proactively manage treatment-related adverse events.

To meet this educational need, Oncology Best Practice™ will bring nationally renowned experts in NSCLC directly to leading cancer centers, large oncology practice groups, and community hospitals throughout the United States. These 1-hour interactive meetings will address the therapeutic needs that persist for patients with lung cancer, as well as current and emerging therapies to address these medical needs. Ample discussion time will allow participants to interact with expert faculty to address challenges in their practice.

What will attending an Oncology Best Practice™ allow me to do?

  • Interact with a nationally recognized expert in lung cancer and local peers at each meeting.
  • Explore the application of clinical data and expert guidelines to common and challenging patient scenarios.
  • Develop strategies for challenging subsets of patients with NSCLC:
    • Managing patients with advanced squamous NSCLC beyond progression.
    • Choosing the optimal therapy for patients with advanced NSCLC receiving first-line immunotherapy.
    • Planning subsequent lines of therapy for patients with oncogene-driven NSCLC who progress on targeted therapy.
  • Discuss the potential clinical implications of recent data on inhibitors of immune checkpoints and growth factor receptors in patients with squamous or nonsquamous NSCLC.
  • Consult with lung cancer experts regarding clinical challenges in your practice.
  • Learn about ongoing clinical trial opportunities for your patients.

Target Audience

This educational activity is directed toward medical oncologists interested in the treatment of patients with lung cancer. Fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of lung cancer are invited to participate.

Learning Objectives

At the conclusion of this activity, participants will be better prepared to:

  • Assess testing methods that should be applied to inform clinical decision making for patients with advanced NSCLC who have progressed following first-line chemotherapy
  • Describe landmark clinical trials that have evaluated patients with advanced NSCLC who have progressed on platinum-based therapeutic approaches
  • Explain strategies to proactively address treatment-related adverse events in patients with advanced NSCLC
  • Construct an algorithm based on clinical and biomarker information for the management of patients who have progressed following platinum-based chemotherapy in either frontline treatment or following frontline immunotherapy


David R. Gandara, MD
Professor of Medicine
Division of Hematology/Oncology
Director, Thoracic Oncology Program
Senior Advisor to the Director
UC Davis Comprehensive Cancer Center
Sacramento, CA

Become a Member

Forgot Password?
Calendar of Events
Filter By